Vertex Pharmaceuticals (VRTX) Financials

$447.09 +1.99 (+0.45%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$446.62 -0.47 (-0.11%)

As of 04:38 AM Eastern

Annual Income Statements for Vertex Pharmaceuticals

This table shows Vertex Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-536	3,620	3,322	2,342	2,712	1,177	2,097	263	-112	-556
Consolidated Net Income / (Loss)	-536	3,620	3,322	2,342	2,712	1,177	2,087	92	-84	-588
Net Income / (Loss) Continuing Operations	-536	3,620	3,322	2,342	2,712	1,177	2,087	92	-84	-588
Total Pre-Tax Income	249	4,380	4,232	2,730	3,117	1,395	600	-16	-67	-558
Total Operating Income	-233	3,832	4,307	2,782	2,856	1,198	635	123	9.94	-467
Total Gross Profit	9,490	8,607	7,850	6,670	5,469	3,615	2,638	2,214	1,492	915
Total Revenue	11,020	9,869	8,931	7,574	6,206	4,163	3,048	2,489	1,702	1,032
Operating Revenue	11,020	9,869	8,931	7,574	6,206	4,163	3,048	2,489	1,702	1,032
Total Cost of Revenue	1,531	1,262	1,080	904	736	548	410	275	210	117
Operating Cost of Revenue	1,531	1,262	1,080	904	736	548	410	275	210	117
Total Operating Expenses	9,723	4,775	3,543	3,888	2,613	2,418	2,003	2,090	1,482	1,382
Selling, General & Admin Expense	1,464	1,137	945	840	771	659	558	496	433	377
Research & Development Expense	8,259	3,690	2,656	3,051	1,830	1,755	1,416	1,325	1,048	996
Other Special Charges / (Income)	-0.50	-52	-58	-3.10	13	4.50	0.00	0.00	-	-
Total Other Income / (Expense), net	481	548	-75	-52	261	197	-35	-139	-77	-91
Interest Expense	31	44	55	62	58	59	72	69	-	-
Interest & Investment Income	598	615	145	4.90	22	64	38	12	-81	-84
Other Income / (Expense), net	-86	-23	-165	4.90	297	192	-0.79	-81	4.13	-6.72
Income Tax Expense	784	760	910	388	405	218	-1,487	-107	17	30
Basic Earnings per Share	($2.08)	$14.05	$12.97	$9.09	$10.44	$4.58	$8.24	$1.06	($0.46)	($2.31)
Weighted Average Basic Shares Outstanding	257.90M	257.70M	256.10M	257.70M	259.80M	256.70M	254.29M	248.86M	244.69M	241.31M
Diluted Earnings per Share	($2.08)	$13.89	$12.82	$9.01	$10.29	$4.51	$8.09	$1.04	($0.46)	($2.31)
Weighted Average Diluted Shares Outstanding	257.90M	260.50M	259.10M	259.90M	263.40M	260.70M	259.19M	253.23M	244.69M	241.31M
Weighted Average Basic & Diluted Shares Outstanding	256.79M	258.31M	257.09M	254.58M	259.96M	259.27M	254.50M	248.60M	243.60M	240.80M

This table shows Vertex Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	646	913	1,045	-3,594	1,100	969	1,035	916	700	819	931
Consolidated Net Income / (Loss)	646	913	1,045	-3,594	1,100	969	1,035	916	700	819	931
Net Income / (Loss) Continuing Operations	646	913	1,045	-3,594	1,100	969	1,035	916	700	819	931
Total Pre-Tax Income	730	1,137	1,224	-3,391	1,279	1,148	1,179	1,162	892	1,077	1,176
Total Operating Income	630	1,026	1,116	-3,515	1,140	989	1,038	1,026	779	1,034	1,127
Total Gross Profit	2,407	2,489	2,379	2,274	2,348	2,150	2,165	2,185	2,108	2,019	2,045
Total Revenue	2,770	2,912	2,772	2,646	2,691	2,518	2,484	2,493	2,375	2,303	2,334
Operating Revenue	2,770	2,912	2,772	2,646	2,691	2,518	2,484	2,493	2,375	2,303	2,334
Total Cost of Revenue	363	423	393	372	343	368	319	309	267	283	289
Operating Cost of Revenue	363	423	393	372	343	368	319	309	267	283	289
Total Operating Expenses	1,777	1,463	1,263	5,788	1,209	1,161	1,127	1,158	1,329	986	918
Selling, General & Admin Expense	396	378	372	372	343	369	264	263	241	267	247
Research & Development Expense	1,000	1,086	891	5,416	866	842	862	896	1,090	717	674
Impairment Charge	379	-	-	-	-	-	-	-	-	-	-
Other Special Charges / (Income)	2.20	-1.20	0.30	0.50	-0.10	-50	1.20	-0.60	-1.90	1.80	-2.60
Total Other Income / (Expense), net	100	111	108	124	140	159	141	135	113	43	50
Interest Expense	3.00	2.80	7.50	9.90	10	11	11	11	11	12	14
Interest & Investment Income	121	128	132	157	181	180	168	145	123	86	46
Other Income / (Expense), net	-18	-15	-17	-23	-31	-9.80	-16	1.60	1.30	-31	17
Income Tax Expense	84	224	179	202	180	179	144	246	192	258	246
Basic Earnings per Share	$2.52	$3.53	$4.05	($13.92)	$4.26	$3.77	$4.01	$3.55	$2.72	$3.18	$3.63
Weighted Average Basic Shares Outstanding	256.90M	257.90M	258M	258.10M	258.20M	257.70M	258M	257.70M	257.40M	256.10M	256.50M
Diluted Earnings per Share	$2.49	$3.62	$4.01	($13.92)	$4.21	$3.71	$3.97	$3.52	$2.69	$3.14	$3.59
Weighted Average Diluted Shares Outstanding	259.50M	257.90M	261M	258.10M	261.10M	260.50M	260.60M	260.40M	260.30M	259.10M	259.50M
Weighted Average Basic & Diluted Shares Outstanding	256.80M	256.79M	257.53M	258.10M	258.05M	258.31M	257.68M	258.09M	257.55M	257.09M	256.69M

This table details how cash moves in and out of Vertex Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-5,800	-140	3,712	811	2,868	462	997	430	416	90
Net Cash From Operating Activities	-493	3,537	4,130	2,644	3,254	1,569	1,270	845	236	-365
Net Cash From Continuing Operating Activities	-493	3,537	4,130	2,644	3,254	1,569	1,270	845	236	-365
Net Income / (Loss) Continuing Operations	-536	3,620	3,322	2,342	2,712	1,177	2,087	92	-84	-588
Consolidated Net Income / (Loss)	-536	3,620	3,322	2,342	2,712	1,177	2,087	92	-84	-588
Depreciation Expense	207	181	148	126	110	107	72	61	61	62
Non-Cash Adjustments To Reconcile Net Income	700	590	652	439	196	180	385	800	320	243
Changes in Operating Assets and Liabilities, net	-864	-854	7.40	-263	236	106	-1,274	-108	-61	-83
Net Cash From Investing Activities	-3,770	-3,142	-321	-341	99	-1,235	-202	-483	51	269
Net Cash From Continuing Investing Activities	-3,770	-3,142	-321	-341	99	-1,235	-202	-483	51	269
Purchase of Property, Plant & Equipment	-298	-200	-205	-235	-260	-75	-95	-99	-57	-45
Acquisitions	0.00	0.00	-296	0.00	0.00	-1,154	0.00	-160	0.00	-80
Purchase of Investments	-7,438	-3,787	-693	-605	-451	-577	-523	-533	-630	-633
Sale and/or Maturity of Investments	4,208	934	920	499	810	571	432	308	758	1,079
Other Investing Activities, net	-242	-89	-48	-	-	-	-15	1.06	-20	-52
Net Cash From Financing Activities	-1,495	-562	-68	-1,478	-505	127	-71	68	133	189
Net Cash From Continuing Financing Activities	-1,495	-562	-68	-1,478	-505	127	-71	68	133	189
Repayment of Debt	6.20	1.80	3.50	-	-1.80	4.80	-	-319	-96	-20
Repurchase of Common Equity	-1,177	-428	0.00	-1,425	-539	-186	-350	0.00	0.00	-
Issuance of Common Equity	115	135	186	102	265	343	289	345	68	186
Other Financing Activities, net	-439	-271	-258	-155	-229	-45	-13	43	75	-0.38
Effect of Exchange Rate Changes	-43	27	-	-13	-	-	-	-	-4.67	-2.83
Cash Interest Paid	31	43	52	56	55	56	66	69	84	86
Cash Income Taxes Paid	1,082	1,677	1,058	476	192	25	12	6.41	-2.58	1.81

This table details how cash moves in and out of Vertex Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	113	-676	657	-4,578	-1,203	-744	963	858	-1,216	1,335	473
Net Cash From Operating Activities	819	585	1,370	-3,754	1,307	235	1,268	1,134	900	1,078	956
Net Cash From Continuing Operating Activities	819	585	1,370	-3,754	1,307	235	1,268	1,134	900	1,078	956
Net Income / (Loss) Continuing Operations	646	913	1,045	-3,594	1,100	969	1,035	916	700	819	931
Consolidated Net Income / (Loss)	646	913	1,045	-3,594	1,100	969	1,035	916	700	819	931
Depreciation Expense	48	47	53	54	54	59	42	41	39	38	37
Non-Cash Adjustments To Reconcile Net Income	584	135	237	146	183	227	116	109	138	162	92
Changes in Operating Assets and Liabilities, net	-460	-510	35	-360	-29	-1,020	75	68	24	59	-104
Net Cash From Investing Activities	-56	-822	-348	-464	-2,136	-887	-118	-304	-1,834	176	-384
Net Cash From Continuing Investing Activities	-56	-822	-348	-464	-2,136	-887	-118	-304	-1,834	176	-384
Purchase of Property, Plant & Equipment	-41	-93	-68	-69	-68	-58	-41	-60	-42	-34	-54
Purchase of Investments	-1,647	-2,159	-1,385	-1,297	-2,599	-989	-407	-549	-1,842	-227	-228
Sale and/or Maturity of Investments	1,638	1,460	1,112	925	711	218	331	335	50	484	194
Other Investing Activities, net	-5.30	-31	-8.10	-23	-180	-58	-1.10	-30	0.00	-	-
Net Cash From Financing Activities	-680	-391	-388	-359	-358	-120	-165	17	-295	40	-60
Net Cash From Continuing Financing Activities	-680	-391	-388	-359	-358	-120	-165	17	-295	40	-60
Repayment of Debt	0.80	0.90	0.90	0.90	3.50	-1.50	1.10	1.10	1.10	1.10	0.70
Repurchase of Common Equity	-426	-418	-308	-320	-131	-150	-117	-28	-133	-	-
Issuance of Common Equity	17	34	8.40	55	17	46	15	59	14	52	37
Other Financing Activities, net	-272	-8.60	-89	-94	-247	-15	-65	-14	-177	-13	-98
Other Net Changes in Cash	31	-	-	-	-	-	-	-	-	-	-
Cash Interest Paid	2.70	2.70	8.10	9.70	10	11	11	11	11	11	14
Cash Income Taxes Paid	184	272	279	497	35	758	300	498	120	218	362

This table presents Vertex Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	22,533	22,730	18,151	13,433	11,752	8,318	6,246	3,546	2,897	2,499
Total Current Assets	9,596	14,144	13,235	9,561	8,133	4,823	3,843	2,649	1,832	1,407
Cash & Equivalents	4,570	10,369	10,504	6,795	5,988	3,109	2,650	1,665	1,184	715
Short-Term Investments	1,546	849	275	730	671	699	518	423	251	328
Accounts Receivable	1,609	1,563	1,442	1,137	885	634	410	281	200	174
Inventories, net	1,205	739	461	353	281	168	124	112	78	57
Prepaid Expenses	666	624	554	546	308	214	141	167	71	55
Plant, Property, & Equipment, net	1,228	1,159	1,108	1,094	0.00	0.00	812	789	698	698
Total Noncurrent Assets	11,709	7,427	3,808	2,778	3,618	3,496	1,591	108	367	394
Long-Term Investments	5,108	2,498	112	-	-	-	-	-	20	0.00
Goodwill	1,088	1,088	1,088	1,002	1,002	1,002	50	50	50	50
Intangible Assets	826	840	604	400	400	400	0.00	29	284	284
Noncurrent Deferred & Refundable Income Taxes	2,331	1,812	1,247	935	883	1,191	1,500	0.83	-	-
Other Noncurrent Operating Assets	2,356	1,189	757	441	1,333	903	41	27	12	6.91
Total Liabilities & Shareholders' Equity	22,533	22,730	18,151	13,433	11,752	8,318	6,246	3,546	2,897	2,499
Total Liabilities	6,124	5,150	4,238	3,333	3,065	2,233	1,811	1,504	1,559	1,405
Total Current Liabilities	3,565	3,547	2,742	2,142	1,878	1,335	1,120	807	793	506
Accounts Payable	413	365	304	195	155	88	111	74	61	75
Accrued Expenses	2,789	2,655	2,127	1,679	1,405	1,117	959	444	315	306
Other Current Liabilities	363	527	312	268	317	130	50	267	17	22
Total Noncurrent Liabilities	2,559	1,602	1,496	1,191	1,188	898	690	696	766	899
Other Noncurrent Operating Liabilities	2,559	1,602	1,496	1,191	1,188	898	690	670	588	504
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	16,410	17,580	13,913	10,100	8,687	6,085	4,435	2,042	1,338	1,094
Total Preferred & Common Equity	16,410	17,580	13,913	10,100	8,687	6,085	4,435	2,029	1,157	940
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	16,410	17,580	13,913	10,100	8,687	6,085	4,435	2,029	1,157	940
Common Stock	6,675	7,452	7,389	6,883	7,897	7,940	7,424	7,160	6,509	6,200
Retained Earnings	9,607	10,142	6,523	3,201	859	-1,853	-2,989	-5,120	-5,374	-5,262
Accumulated Other Comprehensive Income / (Loss)	128	-14	0.80	16	-69	-1.97	0.66	-12	21	1.82

This table presents Vertex Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	22,881	22,533	22,240	20,132	23,917	22,730	21,726	20,349	18,974	18,151	16,706
Total Current Assets	10,009	9,596	9,804	8,942	13,289	14,144	14,696	13,873	12,966	13,235	12,271
Cash & Equivalents	4,675	4,570	5,239	4,580	9,158	10,369	11,110	10,151	9,290	10,504	9,172
Short-Term Investments	1,527	1,546	1,285	1,215	1,013	849	818	1,085	1,124	275	599
Accounts Receivable	1,805	1,609	1,751	1,656	1,793	1,563	1,539	1,556	1,548	1,442	1,385
Inventories, net	1,360	1,205	1,080	915	813	739	689	604	535	461	388
Prepaid Expenses	643	666	449	575	511	624	540	477	469	554	727
Plant, Property, & Equipment, net	1,296	1,228	1,118	1,201	1,173	1,159	1,124	1,122	1,112	1,108	1,119
Total Noncurrent Assets	11,576	11,709	11,318	9,990	9,456	7,427	5,906	5,354	4,897	3,808	3,317
Long-Term Investments	5,157	5,108	4,704	4,393	4,381	2,498	1,700	1,357	1,082	112	-
Goodwill	1,088	1,088	1,088	1,088	1,088	1,088	1,088	1,088	1,088	1,088	1,075
Intangible Assets	441	826	832	838	835	840	604	604	604	604	604
Noncurrent Deferred & Refundable Income Taxes	2,544	2,331	2,309	2,186	1,963	1,812	1,729	1,538	1,360	1,247	1,163
Other Noncurrent Operating Assets	2,346	2,356	2,386	1,485	1,189	1,189	786	767	764	757	475
Total Liabilities & Shareholders' Equity	22,881	22,533	22,240	20,132	23,917	22,730	21,726	20,349	18,974	18,151	16,706
Total Liabilities	6,384	6,124	6,609	5,357	5,371	5,150	5,213	4,879	4,542	4,238	3,677
Total Current Liabilities	3,783	3,565	3,973	3,547	3,796	3,547	3,599	3,352	3,026	2,742	2,609
Accounts Payable	445	413	396	328	351	365	376	363	323	304	127
Accrued Expenses	2,952	2,789	3,220	2,940	2,796	2,655	2,907	2,598	2,326	2,127	2,264
Other Current Liabilities	386	363	358	279	649	527	316	391	377	312	218
Total Noncurrent Liabilities	2,601	2,559	2,636	1,810	1,575	1,602	1,614	1,527	1,516	1,496	1,068
Other Noncurrent Operating Liabilities	2,601	2,559	2,636	1,810	1,575	1,602	1,614	1,527	1,516	1,496	1,068
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	16,496	16,410	15,631	14,775	18,547	17,580	16,513	15,470	14,432	13,913	13,030
Total Preferred & Common Equity	16,496	16,410	15,631	14,775	18,547	17,580	16,513	15,470	14,432	13,913	13,030
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	16,496	16,410	15,631	14,775	18,547	17,580	16,513	15,470	14,432	13,913	13,030
Common Stock	6,175	6,675	6,908	7,104	7,287	7,452	7,342	7,372	7,223	7,389	7,228
Retained Earnings	10,253	9,607	8,694	7,648	11,242	10,142	9,174	8,138	7,223	6,523	5,704
Accumulated Other Comprehensive Income / (Loss)	68	128	29	23	17	-14	-3.00	-40	-13	0.80	98

This table displays calculated financial ratios and metrics derived from Vertex Pharmaceuticals' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.66%	10.51%	17.91%	22.06%	49.08%	36.59%	22.46%	46.20%	64.89%	77.86%
EBITDA Growth	-102.80%	-7.00%	47.32%	-10.72%	117.99%	111.75%	584.48%	36.83%	118.35%	31.32%
EBIT Growth	-108.37%	-8.05%	48.64%	-11.61%	126.88%	119.07%	1,415.40%	197.60%	102.97%	28.46%
NOPAT Growth	-84.15%	-6.33%	41.67%	-3.97%	145.97%	-54.26%	2,459.97%	1,140.37%	102.13%	32.57%
Net Income Growth	-114.80%	8.96%	41.84%	-13.63%	130.43%	-43.62%	2,177.63%	209.05%	85.71%	20.81%
EPS Growth	-114.97%	8.35%	42.29%	-12.44%	128.16%	-44.25%	677.88%	326.09%	80.09%	26.43%
Operating Cash Flow Growth	-113.93%	-14.35%	56.23%	-18.75%	107.32%	23.54%	50.34%	257.87%	164.61%	36.24%
Free Cash Flow Firm Growth	-135.25%	-20.77%	59.52%	-32.73%	992,161.33%	-99.97%	235.55%	131.54%	120.88%	0.31%
Invested Capital Growth	34.20%	27.87%	17.35%	26.98%	-10.94%	79.72%	38,112.63%	-101.75%	-37.46%	480.25%
Revenue Q/Q Growth	3.71%	2.23%	2.64%	6.24%	3.58%	46.72%	-15.62%	8.40%	2.45%	36.02%
EBITDA Q/Q Growth	15.11%	-0.08%	2.93%	-0.46%	7.48%	76.55%	-10.77%	472.61%	470.30%	19.78%
EBIT Q/Q Growth	9.22%	-0.62%	2.92%	-0.64%	7.65%	85.75%	-12.15%	198.77%	117.14%	17.72%
NOPAT Q/Q Growth	0.44%	1.44%	0.18%	13.72%	0.79%	-53.76%	257.20%	231.78%	111.91%	17.63%
Net Income Q/Q Growth	-11.63%	4.32%	1.49%	7.62%	0.78%	-44.46%	214.23%	432.48%	54.93%	15.29%
EPS Q/Q Growth	-4.52%	4.28%	1.26%	8.29%	0.59%	-45.40%	223.60%	33.33%	48.89%	15.69%
Operating Cash Flow Q/Q Growth	41.54%	-19.26%	2.06%	23.53%	1.42%	9.14%	7.36%	10.86%	95.90%	36.60%
Free Cash Flow Firm Q/Q Growth	19.54%	-33.51%	9.24%	21.71%	57.12%	-99.97%	28.51%	-9.93%	497.26%	15.58%
Invested Capital Q/Q Growth	17.78%	33.96%	-7.27%	0.21%	2.29%	81.13%	1,331.31%	-137.51%	-35.23%	-5.45%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.11%	87.21%	87.90%	88.06%	88.14%	86.84%	86.56%	88.95%	87.64%	88.65%
EBITDA Margin	-1.01%	40.43%	48.05%	38.45%	52.57%	35.95%	23.19%	4.15%	4.43%	-39.84%
Operating Margin	-2.11%	38.83%	48.23%	36.73%	46.03%	28.77%	20.84%	4.95%	0.58%	-45.23%
EBIT Margin	-2.89%	38.60%	46.39%	36.80%	50.81%	33.38%	20.82%	1.68%	0.83%	-45.88%
Profit (Net Income) Margin	-4.86%	36.68%	37.20%	30.92%	43.70%	28.27%	68.48%	3.68%	-4.94%	-56.98%
Tax Burden Percent	-215.53%	82.64%	78.49%	85.78%	87.00%	84.36%	347.71%	-584.07%	124.74%	105.45%
Interest Burden Percent	-77.90%	114.98%	102.17%	97.97%	98.86%	100.37%	94.62%	-37.48%	-478.93%	117.78%
Effective Tax Rate	315.53%	17.36%	21.51%	14.22%	13.00%	15.64%	-247.71%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	11.09%	91.98%	120.81%	103.69%	115.45%	57.01%	349.55%	92.43%	2.82%	-183.52%
ROIC Less NNEP Spread (ROIC-NNEP)	19.41%	88.30%	121.45%	104.32%	111.12%	52.24%	354.20%	92.10%	12.21%	-155.02%
Return on Net Nonoperating Assets (RNNOA)	-14.24%	-68.99%	-93.14%	-78.76%	-78.74%	-34.64%	-285.11%	-87.01%	-9.73%	129.80%
Return on Equity (ROE)	-3.15%	22.99%	27.67%	24.93%	36.71%	22.37%	64.44%	5.42%	-6.91%	-53.72%
Cash Return on Invested Capital (CROIC)	-18.11%	67.51%	104.84%	79.92%	127.02%	0.02%	74.05%	0.00%	48.91%	-324.72%
Operating Return on Assets (OROA)	-1.41%	18.64%	26.23%	22.13%	31.42%	19.08%	12.96%	1.30%	0.52%	-19.60%
Return on Assets (ROA)	-2.37%	17.71%	21.04%	18.60%	27.02%	16.16%	42.63%	2.84%	-3.11%	-24.34%
Return on Common Equity (ROCE)	-3.15%	22.99%	27.67%	24.93%	36.71%	22.37%	64.31%	5.11%	-5.96%	-49.43%
Return on Equity Simple (ROE_SIMPLE)	-3.26%	20.59%	23.88%	23.19%	31.22%	19.34%	47.06%	4.52%	-7.27%	-62.57%
Net Operating Profit after Tax (NOPAT)	502	3,167	3,381	2,386	2,485	1,010	2,208	86	6.96	-327
NOPAT Margin	4.56%	32.09%	37.86%	31.51%	40.04%	24.27%	72.47%	3.47%	0.41%	-31.66%
Net Nonoperating Expense Percent (NNEP)	-8.32%	3.68%	-0.64%	-0.63%	4.33%	4.77%	-4.66%	0.34%	-9.39%	-28.51%
Return On Investment Capital (ROIC_SIMPLE)	3.06%	18.01%	24.30%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	13.89%	12.79%	12.10%	11.94%	11.86%	13.16%	13.44%	11.05%	12.36%	11.35%
SG&A Expenses to Revenue	13.29%	11.52%	10.58%	11.09%	12.42%	15.82%	18.30%	19.93%	25.43%	36.48%
R&D to Revenue	74.94%	37.39%	29.74%	40.28%	29.48%	42.15%	46.48%	53.23%	61.55%	96.47%
Operating Expenses to Revenue	88.23%	48.38%	39.67%	51.33%	42.11%	58.07%	65.72%	83.99%	87.05%	133.88%
Earnings before Interest and Taxes (EBIT)	-319	3,809	4,143	2,787	3,153	1,390	634	42	14	-474
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-112	3,991	4,291	2,913	3,262	1,497	707	103	75	-411
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.32	5.96	5.33	5.53	7.07	9.25	9.55	18.68	15.80	32.89
Price to Tangible Book Value (P/TBV)	7.15	6.70	6.07	6.42	8.44	12.02	9.66	19.44	22.23	51.08
Price to Revenue (P/Rev)	9.41	10.62	8.30	7.37	9.90	13.53	13.90	15.23	10.73	29.95
Price to Earnings (P/E)	0.00	28.97	22.31	23.84	22.66	47.84	20.20	143.84	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	3.45%	4.48%	4.19%	4.41%	2.09%	4.95%	0.70%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	17.83	23.58	20.93	18.76	27.02	23.05	30.92	0.00	91.09	99.75
Enterprise Value to Revenue (EV/Rev)	8.39	9.23	7.08	6.38	8.83	12.61	12.86	14.41	10.17	29.36
Enterprise Value to EBITDA (EV/EBITDA)	0.00	22.84	14.74	16.59	16.80	35.08	55.43	347.36	229.33	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	23.92	15.27	17.33	17.38	37.77	61.76	856.84	1,230.35	0.00
Enterprise Value to NOPAT (EV/NOPAT)	184.24	28.78	18.70	20.24	22.05	51.96	17.74	415.77	2,488.22	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	25.76	15.31	18.27	16.84	33.45	30.84	42.45	73.30	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	39.20	21.55	26.27	20.04	190,518.77	41.76	128.28	143.31	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.02	0.26	0.32
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.03	0.24
Financial Leverage	-0.73	-0.78	-0.77	-0.76	-0.71	-0.66	-0.80	-0.94	-0.80	-0.84
Leverage Ratio	1.33	1.30	1.32	1.34	1.36	1.38	1.51	1.91	2.22	2.21
Compound Leverage Factor	-1.04	1.49	1.34	1.31	1.34	1.39	1.43	-0.71	-10.63	2.60
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2.06%	20.94%	24.43%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.08%	18.87%	6.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.98%	2.07%	18.43%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.66%	10.73%	10.62%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	97.28%	68.33%	64.95%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.42	4.70	-0.86
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-19.81	-15.22	1.87
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.20	0.46	-0.65
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	50.96	-1.08
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-23.71	-165.08	2.35
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.24	5.03	-0.82
Altman Z-Score	11.52	14.39	12.94	12.30	14.19	16.37	14.71	14.47	5.47	10.48
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.21%	5.78%	13.79%	7.98%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.69	3.99	4.83	4.46	4.33	3.61	3.43	3.28	2.31	2.78
Quick Ratio	2.17	3.60	4.46	4.04	4.02	3.33	3.19	2.94	2.06	2.40
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-820	2,325	2,934	1,839	2,734	0.28	938	280	121	-578
Operating Cash Flow to CapEx	-165.47%	1,765.12%	2,017.54%	1,124.89%	1,252.31%	2,081.30%	1,330.85%	849.86%	417.42%	-806.66%
Free Cash Flow to Firm to Interest Expense	-26.78	52.71	53.54	29.91	46.98	0.00	12.95	4.03	0.00	0.00
Operating Cash Flow to Interest Expense	-16.10	80.21	75.36	42.98	55.90	26.83	17.53	12.19	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-25.83	75.67	71.63	39.16	51.44	25.54	16.21	10.76	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.49	0.48	0.57	0.60	0.62	0.57	0.62	0.77	0.63	0.43
Accounts Receivable Turnover	6.95	6.57	6.93	7.49	8.17	7.98	8.82	10.33	9.10	8.27
Inventory Turnover	1.57	2.10	2.66	2.85	3.28	3.75	3.47	2.90	3.12	2.66
Fixed Asset Turnover	9.23	8.70	8.11	0.00	0.00	0.00	3.81	3.35	2.44	1.46
Accounts Payable Turnover	3.94	3.77	4.33	5.17	6.07	5.52	4.43	4.06	3.09	1.60
Days Sales Outstanding (DSO)	52.54	55.58	52.70	48.72	44.67	45.73	41.38	35.33	40.12	44.16
Days Inventory Outstanding (DIO)	231.83	173.42	137.46	127.94	111.12	97.23	105.25	125.66	116.90	137.17
Days Payable Outstanding (DPO)	92.76	96.70	84.28	70.66	60.16	66.16	82.43	89.85	118.27	227.65
Cash Conversion Cycle (CCC)	191.62	132.30	105.88	106.00	95.63	76.81	64.20	71.14	38.75	-46.32
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,186	3,864	3,022	2,575	2,028	2,277	1,267	-3.33	190	304
Invested Capital Turnover	2.44	2.87	3.19	3.29	2.88	2.35	4.82	26.66	6.89	5.80
Increase / (Decrease) in Invested Capital	1,322	842	447	547	-249	1,010	1,270	-193	-114	251
Enterprise Value (EV)	92,483	91,133	63,237	48,309	54,798	52,495	39,180	35,868	17,306	30,305
Market Capitalization	103,707	104,849	74,127	55,834	61,457	56,303	42,349	37,900	18,273	30,919
Book Value per Share	$63.72	$68.22	$54.20	$39.72	$33.41	$23.66	$17.36	$8.02	$4.66	$3.83
Tangible Book Value per Share	$56.29	$60.74	$47.61	$34.21	$28.01	$18.21	$17.16	$7.71	$3.31	$2.46
Total Capital	16,410	17,580	13,913	10,100	8,687	6,085	4,435	2,085	1,693	1,447
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	43	354	354
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	20	35	267
Net Debt	-11,224	-13,716	-10,891	-7,525	-6,659	-3,808	-3,168	-2,046	-1,148	-768
Capital Expenditures (CapEx)	298	200	205	235	260	75	95	99	57	45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-84	-622	-286	-106	-403	-320	-445	-224	-124	-134
Debt-free Net Working Capital (DFNWC)	6,032	10,597	10,493	7,419	6,256	3,488	2,723	1,864	1,358	988
Net Working Capital (NWC)	6,032	10,597	10,493	7,419	6,256	3,488	2,723	1,842	1,039	901
Net Nonoperating Expense (NNE)	1,038	-453	59	44	-227	-167	121	-5.36	91	261
Net Nonoperating Obligations (NNO)	-11,224	-13,716	-10,891	-7,525	-6,659	-3,808	-3,168	-2,046	-1,148	-790
Total Depreciation and Amortization (D&A)	207	181	148	126	110	107	72	61	61	62
Debt-free, Cash-free Net Working Capital to Revenue	-0.76%	-6.30%	-3.20%	-1.40%	-6.49%	-7.69%	-14.62%	-9.02%	-7.28%	-12.94%
Debt-free Net Working Capital to Revenue	54.73%	107.37%	117.49%	97.94%	100.81%	83.79%	89.34%	74.91%	79.81%	95.69%
Net Working Capital to Revenue	54.73%	107.37%	117.49%	97.94%	100.81%	83.79%	89.34%	74.00%	61.04%	87.28%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($2.08)	$14.05	$12.97	$9.09	$10.44	$4.58	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic Shares Outstanding	257.90M	257.70M	256.10M	257.70M	259.84M	256.73M	0.00	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	($2.08)	$13.89	$12.82	$9.01	$10.29	$4.51	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	257.90M	260.50M	259.10M	259.90M	263.40M	260.67M	0.00	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	256.79M	258.31M	257.09M	254.58M	259.96M	259.27M	0.00	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-163	3,124	3,336	2,384	2,496	1,014	465	275	7.84	-325
Normalized NOPAT Margin	-1.48%	31.66%	37.35%	31.47%	40.23%	24.36%	15.25%	11.05%	0.46%	-31.51%
Pre Tax Income Margin	2.26%	44.38%	47.39%	36.05%	50.23%	33.51%	19.70%	-0.63%	-3.96%	-54.03%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-10.42	86.38	75.59	45.32	54.17	23.76	8.75	0.60	0.00	0.00
NOPAT to Interest Expense	16.40	71.81	61.69	38.80	42.70	17.27	30.47	1.24	0.00	0.00
EBIT Less CapEx to Interest Expense	-20.15	81.83	71.86	41.50	49.71	22.47	7.44	-0.83	0.00	0.00
NOPAT Less CapEx to Interest Expense	6.68	67.27	57.96	34.98	38.23	15.98	29.16	-0.19	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-219.77%	11.81%	0.00%	60.86%	19.88%	15.81%	16.77%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Vertex Pharmaceuticals' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.96%	15.66%	11.61%	6.11%	13.30%	9.34%	6.39%	13.52%	13.22%	11.10%	17.65%
EBITDA Growth	-43.11%	1.92%	8.30%	-425.77%	41.84%	-0.30%	-9.85%	0.37%	-18.42%	13.30%	4.61%
EBIT Growth	-44.74%	3.31%	7.55%	-444.14%	42.04%	-2.36%	-10.64%	-0.02%	-19.40%	13.29%	4.28%
NOPAT Growth	-43.08%	-1.23%	4.60%	-404.04%	60.20%	6.17%	2.27%	-7.55%	-26.40%	1.27%	7.42%
Net Income Growth	-41.22%	-5.76%	0.98%	-492.44%	57.13%	18.31%	11.26%	12.98%	-8.17%	6.34%	9.23%
EPS Growth	-40.86%	-2.43%	1.01%	-495.45%	56.51%	18.15%	10.59%	12.46%	-9.12%	5.37%	9.45%
Operating Cash Flow Growth	-37.33%	149.19%	7.99%	-430.89%	45.19%	-78.25%	32.75%	-0.47%	-5.89%	8.38%	3.05%
Free Cash Flow Firm Growth	-656.55%	-6,265.72%	-143.94%	-780.57%	-122.58%	-102.30%	536.14%	-10.37%	57.51%	48.12%	-16.56%
Invested Capital Growth	28.66%	34.20%	52.63%	59.43%	36.00%	27.87%	-11.49%	7.33%	10.03%	17.35%	26.81%
Revenue Q/Q Growth	-4.87%	5.05%	4.77%	-1.67%	6.87%	1.38%	-0.39%	4.99%	3.13%	-1.35%	6.29%
EBITDA Q/Q Growth	-37.51%	-8.24%	133.08%	-399.86%	11.96%	-2.50%	-0.48%	30.56%	-21.30%	-11.84%	10.80%
EBIT Q/Q Growth	-39.42%	-8.03%	131.08%	-419.21%	13.24%	-4.26%	-0.56%	31.74%	-22.16%	-12.37%	11.25%
NOPAT Q/Q Growth	-32.36%	-13.54%	138.75%	-351.15%	17.39%	-8.44%	12.63%	32.33%	-22.20%	-11.81%	1.82%
Net Income Q/Q Growth	-29.21%	-12.67%	129.09%	-426.81%	13.50%	-6.42%	13.06%	30.85%	-14.54%	-11.99%	14.81%
EPS Q/Q Growth	-31.22%	-9.73%	128.81%	-430.64%	13.48%	-6.55%	12.78%	30.86%	-14.33%	-12.53%	14.70%
Operating Cash Flow Q/Q Growth	40.08%	-57.32%	136.49%	-387.28%	456.95%	-81.50%	11.81%	26.06%	-16.55%	12.86%	-16.17%
Free Cash Flow Firm Q/Q Growth	-18.08%	11.98%	86.45%	-5,272.78%	-893.51%	-100.61%	109.85%	78.27%	1.36%	67.76%	-70.43%
Invested Capital Q/Q Growth	-0.91%	17.78%	-3.99%	14.83%	3.35%	33.96%	0.28%	-2.05%	-2.82%	-7.27%	21.60%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	86.90%	85.46%	85.84%	85.94%	87.27%	85.38%	87.17%	87.62%	88.76%	87.70%	87.60%
EBITDA Margin	23.86%	36.32%	41.58%	-131.68%	43.18%	41.22%	42.85%	42.89%	34.49%	45.20%	50.58%
Operating Margin	22.75%	35.23%	40.27%	-132.85%	42.35%	39.26%	41.80%	41.17%	32.80%	44.88%	48.27%
EBIT Margin	22.11%	34.72%	39.66%	-133.72%	41.19%	38.87%	41.16%	41.23%	32.86%	43.53%	49.00%
Profit (Net Income) Margin	23.33%	31.35%	37.71%	-135.83%	40.87%	38.48%	41.69%	36.73%	29.47%	35.56%	39.86%
Tax Burden Percent	88.49%	80.33%	85.40%	105.97%	85.97%	84.42%	87.80%	78.84%	78.50%	76.05%	79.10%
Interest Burden Percent	119.25%	112.40%	111.34%	95.86%	115.41%	117.26%	115.36%	112.99%	114.25%	107.42%	102.84%
Effective Tax Rate	11.51%	19.67%	14.60%	0.00%	14.03%	15.58%	12.20%	21.16%	21.50%	23.95%	20.90%
Return on Invested Capital (ROIC)	48.92%	68.93%	100.30%	-257.64%	107.01%	95.00%	115.34%	111.03%	84.59%	108.92%	113.98%
ROIC Less NNEP Spread (ROIC-NNEP)	48.24%	68.22%	99.55%	-247.69%	106.09%	93.91%	114.28%	110.06%	83.70%	108.57%	113.51%
Return on Net Nonoperating Assets (RNNOA)	-35.67%	-50.06%	-76.98%	186.57%	-83.79%	-73.38%	-90.52%	-87.74%	-65.18%	-83.26%	-84.18%
Return on Equity (ROE)	13.26%	18.88%	23.31%	-71.06%	23.22%	21.63%	24.82%	23.29%	19.41%	25.66%	29.80%
Cash Return on Invested Capital (CROIC)	-36.45%	-18.11%	-27.95%	-24.50%	71.49%	67.51%	113.82%	104.46%	103.30%	104.84%	92.16%
Operating Return on Assets (OROA)	10.49%	16.91%	19.17%	-68.30%	19.56%	18.77%	20.68%	21.81%	18.21%	24.62%	29.08%
Return on Assets (ROA)	11.07%	15.27%	18.23%	-69.37%	19.41%	18.58%	20.94%	19.43%	16.33%	20.11%	23.65%
Return on Common Equity (ROCE)	13.26%	18.88%	23.31%	-71.06%	23.22%	21.63%	24.82%	23.29%	19.41%	25.66%	29.80%
Return on Equity Simple (ROE_SIMPLE)	-5.99%	0.00%	-3.07%	-3.32%	21.67%	0.00%	21.01%	21.75%	22.59%	0.00%	25.12%
Net Operating Profit after Tax (NOPAT)	558	824	953	-2,460	980	834	911	809	611	786	891
NOPAT Margin	20.13%	28.30%	34.39%	-93.00%	36.41%	33.14%	36.70%	32.46%	25.75%	34.13%	38.18%
Net Nonoperating Expense Percent (NNEP)	0.69%	0.71%	0.74%	-9.95%	0.92%	1.09%	1.06%	0.98%	0.90%	0.36%	0.47%
Return On Investment Capital (ROIC_SIMPLE)	3.38%	5.02%	-	-	-	4.75%	-	-	-	5.65%	-
Cost of Revenue to Revenue	13.10%	14.54%	14.16%	14.06%	12.73%	14.62%	12.83%	12.38%	11.24%	12.30%	12.40%
SG&A Expenses to Revenue	14.31%	12.97%	13.41%	14.07%	12.74%	14.66%	10.62%	10.53%	10.15%	11.61%	10.57%
R&D to Revenue	36.08%	37.30%	32.14%	204.71%	32.18%	33.46%	34.70%	35.95%	45.89%	31.12%	28.87%
Operating Expenses to Revenue	64.15%	50.23%	45.56%	218.79%	44.92%	46.12%	45.37%	46.45%	55.96%	42.82%	39.34%
Earnings before Interest and Taxes (EBIT)	613	1,011	1,099	-3,538	1,108	979	1,022	1,028	780	1,002	1,144
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	661	1,058	1,153	-3,484	1,162	1,038	1,064	1,069	819	1,041	1,181
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	7.55	6.32	7.68	8.19	5.82	5.96	5.44	5.86	5.61	5.33	5.70
Price to Tangible Book Value (P/TBV)	8.32	7.15	8.75	9.41	6.50	6.70	6.06	6.58	6.36	6.07	6.54
Price to Revenue (P/Rev)	11.22	9.41	11.30	11.70	10.60	10.62	9.30	9.54	8.80	8.30	8.53
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	26.86	28.97	25.87	26.94	24.85	22.31	22.69
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	3.72%	3.45%	3.87%	3.71%	4.02%	4.48%	4.41%
Enterprise Value to Invested Capital (EV/IC)	22.02	17.83	24.71	24.15	23.39	23.58	26.39	27.13	23.67	20.93	19.79
Enterprise Value to Revenue (EV/Rev)	10.19	8.39	10.24	10.72	9.17	9.23	7.88	8.21	7.55	7.08	7.41
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	21.56	22.84	19.06	18.99	16.93	14.74	15.47
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	22.58	23.92	19.86	19.73	17.58	15.27	16.02
Enterprise Value to NOPAT (EV/NOPAT)	0.00	184.24	217.72	139.25	26.43	28.78	24.38	25.18	21.97	18.70	19.11
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	23.69	25.76	17.38	19.18	17.06	15.31	15.94
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	37.71	39.20	21.77	26.89	24.01	21.55	24.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.74	-0.73	-0.77	-0.75	-0.79	-0.78	-0.79	-0.80	-0.78	-0.77	-0.74
Leverage Ratio	1.34	1.33	1.37	1.34	1.30	1.30	1.30	1.31	1.31	1.32	1.30
Compound Leverage Factor	1.59	1.50	1.52	1.28	1.50	1.52	1.50	1.48	1.50	1.41	1.34
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	13.23	11.72	12.40	14.33	13.78	13.98	12.13	12.96	12.48	12.37	14.04
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.65	2.69	2.47	2.52	3.50	3.99	4.08	4.14	4.28	4.83	4.70
Quick Ratio	2.12	2.17	2.08	2.10	3.15	3.60	3.74	3.82	3.95	4.46	4.28
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-587	-497	-565	-4,170	-78	-7.81	1,286	613	344	339	202
Operating Cash Flow to CapEx	2,012.04%	631.32%	2,023.34%	-5,440.00%	1,910.23%	403.79%	3,124.14%	1,903.36%	2,137.53%	3,209.52%	1,762.92%
Free Cash Flow to Firm to Interest Expense	-195.72	-177.60	-75.33	-421.19	-7.46	-0.74	117.96	54.70	30.15	29.23	14.75
Operating Cash Flow to Interest Expense	272.97	208.79	182.64	-379.15	125.63	22.13	116.37	101.29	78.94	92.97	69.74
Operating Cash Flow Less CapEx to Interest Expense	259.40	175.71	173.61	-386.12	119.06	16.65	112.64	95.96	75.25	90.07	65.79
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.47	0.49	0.48	0.51	0.47	0.48	0.50	0.53	0.55	0.57	0.59
Accounts Receivable Turnover	6.17	6.95	6.46	6.44	6.10	6.57	6.60	6.58	6.48	6.93	7.00
Inventory Turnover	1.43	1.57	1.67	1.85	1.98	2.10	2.19	2.36	2.52	2.66	2.89
Fixed Asset Turnover	8.99	9.23	9.48	8.90	8.92	8.70	8.61	8.55	8.30	8.11	0.00
Accounts Payable Turnover	3.89	3.94	3.82	4.06	3.97	3.77	4.68	4.09	4.43	4.33	8.20
Days Sales Outstanding (DSO)	59.16	52.54	56.49	56.71	59.87	55.58	55.27	55.47	56.30	52.70	52.14
Days Inventory Outstanding (DIO)	255.68	231.83	218.80	197.73	183.91	173.42	166.91	154.37	144.82	137.46	126.10
Days Payable Outstanding (DPO)	93.72	92.76	95.48	89.99	92.02	96.70	77.93	89.17	82.32	84.28	44.52
Cash Conversion Cycle (CCC)	221.13	191.62	179.82	164.45	151.75	132.30	144.25	120.67	118.80	105.88	133.72
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,139	5,186	4,403	4,586	3,994	3,864	2,885	2,877	2,937	3,022	3,259
Invested Capital Turnover	2.43	2.44	2.92	2.77	2.94	2.87	3.14	3.42	3.29	3.19	2.99
Increase / (Decrease) in Invested Capital	1,145	1,322	1,518	1,710	1,057	842	-374	197	268	447	689
Enterprise Value (EV)	113,139	92,483	108,810	110,766	93,423	91,133	76,122	78,041	69,506	63,237	64,485
Market Capitalization	124,497	103,707	120,038	120,955	107,975	104,849	89,750	90,635	81,002	74,127	74,255
Book Value per Share	$64.24	$63.72	$60.56	$57.25	$71.80	$68.22	$63.98	$60.07	$56.14	$54.20	$50.81
Tangible Book Value per Share	$58.29	$56.29	$53.12	$49.79	$64.36	$60.74	$57.43	$53.50	$49.56	$47.61	$44.26
Total Capital	16,496	16,410	15,631	14,775	18,547	17,580	16,513	15,470	14,432	13,913	13,030
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-11,358	-11,224	-11,228	-10,189	-14,553	-13,716	-13,628	-12,594	-11,496	-10,891	-9,771
Capital Expenditures (CapEx)	41	93	68	69	68	58	41	60	42	34	54
Debt-free, Cash-free Net Working Capital (DFCFNWC)	24	-84	-694	-401	-679	-622	-832	-716	-475	-286	-109
Debt-free Net Working Capital (DFNWC)	6,226	6,032	5,831	5,394	9,493	10,597	11,096	10,521	9,940	10,493	9,662
Net Working Capital (NWC)	6,226	6,032	5,831	5,394	9,493	10,597	11,096	10,521	9,940	10,493	9,662
Net Nonoperating Expense (NNE)	-89	-89	-92	1,133	-120	-134	-124	-107	-88	-33	-39
Net Nonoperating Obligations (NNO)	-11,358	-11,224	-11,228	-10,189	-14,553	-13,716	-13,628	-12,594	-11,496	-10,891	-9,771
Total Depreciation and Amortization (D&A)	48	47	53	54	54	59	42	41	39	38	37
Debt-free, Cash-free Net Working Capital to Revenue	0.22%	-0.76%	-6.53%	-3.88%	-6.66%	-6.30%	-8.62%	-7.53%	-5.15%	-3.20%	-1.25%
Debt-free Net Working Capital to Revenue	56.09%	54.73%	54.88%	52.18%	93.20%	107.37%	114.94%	110.69%	107.94%	117.49%	111.05%
Net Working Capital to Revenue	56.09%	54.73%	54.88%	52.18%	93.20%	107.37%	114.94%	110.69%	107.94%	117.49%	111.05%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.52	$3.53	$4.05	($13.92)	$4.26	$3.77	$4.01	$3.55	$2.72	$3.18	$3.63
Adjusted Weighted Average Basic Shares Outstanding	256.90M	257.90M	258M	258.10M	258.20M	257.70M	258M	257.70M	257.40M	256.10M	256.50M
Adjusted Diluted Earnings per Share	$2.49	$3.62	$4.01	($13.92)	$4.21	$3.71	$3.97	$3.52	$2.69	$3.14	$3.59
Adjusted Weighted Average Diluted Shares Outstanding	259.50M	257.90M	261M	258.10M	261.10M	260.50M	260.60M	260.40M	260.30M	259.10M	259.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	256.80M	256.79M	257.53M	258.10M	258.05M	258.31M	257.68M	258.09M	257.55M	257.09M	256.69M
Normalized Net Operating Profit after Tax (NOPAT)	895	823	954	-2,460	980	792	912	809	610	787	889
Normalized NOPAT Margin	32.30%	28.27%	34.40%	-92.98%	36.40%	31.46%	36.74%	32.44%	25.69%	34.19%	38.09%
Pre Tax Income Margin	26.37%	39.03%	44.16%	-128.18%	47.54%	45.58%	47.48%	46.59%	37.54%	46.76%	50.40%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	204.17	361.11	146.59	-357.35	106.57	92.33	93.78	91.79	68.45	86.41	83.50
NOPAT to Interest Expense	185.85	294.37	127.11	-248.51	94.19	78.73	83.62	72.25	53.64	67.76	65.05
EBIT Less CapEx to Interest Expense	190.60	328.04	137.56	-364.32	99.99	86.85	90.06	86.46	64.75	83.52	79.54
NOPAT Less CapEx to Interest Expense	172.28	261.30	118.09	-255.48	87.61	73.24	79.89	66.93	49.95	64.86	61.09
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-148.85%	-219.77%	-189.39%	-146.56%	10.60%	11.81%	8.02%	4.79%	4.07%	0.00%	11.25%

Frequently Asked Questions About Vertex Pharmaceuticals' Financials

When does Vertex Pharmaceuticals's fiscal year end?

According to the most recent income statement we have on file, Vertex Pharmaceuticals' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Vertex Pharmaceuticals' net income changed over the last 9 years?

Vertex Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$535.60 million in 2024, falling from -$588.18 million in 2015. The previous period was $3.62 billion in 2023. See where experts think Vertex Pharmaceuticals is headed by visiting Vertex Pharmaceuticals' forecast page.

What is Vertex Pharmaceuticals's operating income?

Vertex Pharmaceuticals's total operating income in 2024 was -$232.90 million, based on the following breakdown:

Total Gross Profit: $9.49 billion
Total Operating Expenses: $9.72 billion

How has Vertex Pharmaceuticals revenue changed over the last 9 years?

Over the last 9 years, Vertex Pharmaceuticals' total revenue changed from $1.03 billion in 2015 to $11.02 billion in 2024, a change of 967.5%.

How much debt does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals' total liabilities were at $6.12 billion at the end of 2024, a 18.9% increase from 2023, and a 335.9% increase since 2015.

How much cash does Vertex Pharmaceuticals have?

In the past 9 years, Vertex Pharmaceuticals' cash and equivalents has ranged from $714.77 million in 2015 to $10.50 billion in 2022, and is currently $4.57 billion as of their latest financial filing in 2024.

How has Vertex Pharmaceuticals' book value per share changed over the last 9 years?

Over the last 9 years, Vertex Pharmaceuticals' book value per share changed from 3.83 in 2015 to 63.72 in 2024, a change of 1,565.7%.

Related Companies

This page (NASDAQ:VRTX) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Financials

Frequently Asked Questions About Vertex Pharmaceuticals' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Financials

Annual Income Statements for Vertex Pharmaceuticals

Quarterly Income Statements for Vertex Pharmaceuticals

Annual Cash Flow Statements for Vertex Pharmaceuticals

Quarterly Cash Flow Statements for Vertex Pharmaceuticals

Annual Balance Sheets for Vertex Pharmaceuticals

Quarterly Balance Sheets for Vertex Pharmaceuticals

Annual Metrics And Ratios for Vertex Pharmaceuticals

Quarterly Metrics And Ratios for Vertex Pharmaceuticals

Frequently Asked Questions About Vertex Pharmaceuticals' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools